Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma

Clinical trial NCT07539688 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07539688
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory B-cell Lymphoma Diffuse Large B-cell Lymphoma Inert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)

Start date: 2026-05-01
Primary completion: 2029-03-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.